Gilead Sciences (GILD) Net Income - Minority (2011 - 2021)
Gilead Sciences (GILD) posted Net Income - Minority of -$7.0 million for Q2 2021, up 41.67% quarter-over-quarter from -$12.0 million in Q1 2021, and up 93.91% year-on-year from -$3.6 million in Q2 2020.
Gilead Sciences (GILD) Net Income - Minority (2011 - 2021) Analysis & Trends
Gilead Sciences (GILD) has reported Net Income - Minority for 11 consecutive years, with -$7.0 million the latest figure, recorded in Q2 2021.
- Net Income - Minority for Q2 2021 came in at -$7.0 million, up 93.91% year-over-year; the trailing twelve-month figure through Jun 2021 was -$7.0 million (up 93.91% YoY), and the FY2020 annual result was -$19.0 million, up 84.8% from the prior year.
- Net Income - Minority was -$7.0 million for Q2 2021 at Gilead Sciences, up from -$12.0 million in the prior quarter.
- Over five years, Net Income - Minority peaked at -$7.0 million in Q2 2021 and troughed at -$476.0 million in Q1 2017.
- Average Net Income - Minority over 5 years is -$144.2 million, with a median of -$120.0 million recorded in 2019.
- Year-over-year, Net Income - Minority plunged 149.15% in 2018 and jumped 93.91% in 2021.
- Over 5 years, Net Income - Minority stood at -$59.0 million in 2017, then slumped by 149.15% to -$147.0 million in 2018, then grew by 14.97% to -$125.0 million in 2019, then soared by 84.8% to -$19.0 million in 2020, then soared by 63.16% to -$7.0 million in 2021.
- Per Business Quant data, the three most recent Net Income - Minority figures were -$7.0 million in Q2 2021, -$12.0 million in Q1 2021, and -$19.0 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -7.00 Mn |
| Mar 31, 2021 | -12.00 Mn |
| Dec 31, 2020 | -19.00 Mn |
| Sep 30, 2020 | -26.00 Mn |
| Jun 30, 2020 | -115.00 Mn |
| Mar 31, 2020 | -112.00 Mn |
| Dec 31, 2019 | -125.00 Mn |
| Sep 30, 2019 | -132.00 Mn |
| Jun 30, 2019 | -135.00 Mn |
| Mar 31, 2019 | -140.00 Mn |
| Dec 31, 2018 | -147.00 Mn |
| Sep 30, 2018 | -146.00 Mn |
| Jun 30, 2018 | -62.00 Mn |
| Mar 31, 2018 | -60.00 Mn |
| Dec 31, 2017 | -59.00 Mn |
| Sep 30, 2017 | -409.00 Mn |
| Jun 30, 2017 | -414.00 Mn |
| Mar 31, 2017 | -476.00 Mn |
| Dec 31, 2016 | -476.00 Mn |
| Sep 30, 2016 | -492.00 Mn |